⚠ A Ministry Decides How Big China IsModerate threat

China is the clearest case in this collection of a market whose size is a number somebody wrote down.

In June 2023 the China National Health Commission published the 14th five-year plan quota for major medical equipment. Under it, "the government will allow for the sale of 559 new surgical robots into China, which could include da Vinci surgical systems as well as surgical systems introduced by others". As of 31 December 2025 Intuitive had placed 162 da Vinci systems under that quota and 5 under special approval¹. Future sales are uncertain, depend on hospitals completing tender processes, and are open to every competitor; Intuitive adds that its ability even to track the number available "is limited by provincial and national agencies making such information publicly available."

That is a national addressable market defined administratively, allocated by tender, and shared with domestic entrants. Of the fourteen competitors Intuitive names, eight are Chinese or Asian — Beijing Surgerii, Harbin Sizhe Rui, Medicaroid, meerecompany, Shandong Weigao, Shanghai Microport Medbot, Shenzhen Edge Medical, SS Innovations² — and the company states plainly that it does "expect increasing competition within China for robotic-assisted systems."

The recurring revenue is under separate pressure. "Since 2022, several provinces in China have implemented significant limits on what hospitals can charge patients for surgeries using robotic surgical technology, including soft tissue surgery. These limits have impacted the number of procedures performed in those provinces as well as pricing of our instruments and accessories"³. Intuitive says the effect has not been material because only a small part of its Chinese installed base sits in the affected provinces, and then says the thing that matters: it cannot assure that other provinces will not do the same, and expects "to continue to face increased pricing pressure."

Intuitive's structure there is a majority-owned joint venture with Fosun Pharma, which since 2019 has run direct distribution and since August 2023 has held a licence to manufacture the da Vinci Xi locally⁴. That is the right structure for the market and it is also a Chinese manufacturing operation supplying a Chinese state customer under a Chinese quota.

The number that quantifies the threat is the quota itself: 559 systems for the entire country, of which Intuitive has taken 167. There is no equivalent constraint in any other market it sells to, and no commercial action that changes it.